LivaNova (LIVN) Q3 2026 Earnings Call Transcript

LivaNova reported results from its Q3 2026 earnings call with total revenue of $393.1 million, up 10.0% on a constant-currency basis, driven by commercial execution and demand across cardiopulmonary and epilepsy technologies. Cardiopulmonary revenue reached $225.3 million (+10.9%), while neuromodulation revenue rose to $166.1 million (+11.2%). The company raised full-year revenue guidance to 9%–10% (constant currency) and adjusted diluted EPS guidance to $4.40–$4.50. For the quarter, adjusted diluted EPS was $1.23 versus $1.11 a year earlier. Adjusted free cash flow was $55.8 million, and cash and equivalents totaled $563.5 million at Sept. 30, 2026. Essenz model placements are expected to represent 80% of 2026 unit placements.